The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The article highlights loss of earnings due to hospital visits. Another very valid point for Feraccru against IV
Continued from belowolerated by 67% of patients, and 50% of patients, who did not tolerate other oral forms of iron, tolerated ferric maltol [24]. Recently, an open-label, Phase 3B non-inferiority trial compared ferric maltol and intravenous iron, focusing on the loss of productivity in IBD patients [25]. Ferric maltol was not inferior to intravenous iron to achieve normalization or increase in hemoglobin values of =2 g/dL after three months of follow-up [25]. Oral iron was not associated with a reduction in productivity [25]. In contrast, 50% of the intravenous group patients lost at least one day of work, and 6.7% of them lost four-to-six working days, causing up to 775 € of daily losses per patient [25]. Interestingly, the physical component summary of the short form health survey (SF-36) and the mental component summary (MCS) values were slightly higher (p-value not significant) in patients treated with oral medication, suggesting a greater improvement in quality of life at the end of the study period [26]. In addition, total treatment costs per patient were lower in the oral drug group than in the intravenous arm (302.27 € vs. 489.37 €, respectively) [27]. Influencing factors on the high cost of intravenous treatment were not only the greater cost of the drug, but also the number of hospitalizations/outpatient visits for each patient (2.30) [27].
Important piece from article posted..... basically IV not possible during pandemic so give Feraccru. Simple !
3.3. Ferric Maltol
In recent years, a new oral iron therapy composed of a complex of ferric iron (Fe+++) and maltol, a sugar derivative, has been developed and is now available [29]. Free iron can damage the intestinal mucosa and modify the gut microbiota [29]. The ferric maltol complex makes iron stable and prevents the formation of iron hydroxide polymers, increasing iron bioavailability and reducing the risk of mucosal toxicity [29]. A randomized Phase 3 study evaluated the efficacy and safety of ferric maltol in IBD patients with iron-deficiency anemia who were unresponsive or intolerant to oral ferrous forms [20]. The drug allowed a rapid improvement in Hb values, since there was a mean Hb increase of 1.04 g/dL, compared to the placebo, after four weeks of treatment [20]. Furthermore, the mean Hb value in patients treated with ferric maltol was significantly higher than in the placebo group, after 12 weeks, with a mean Hb increase of 2.2 g/dL [20]. There was no difference in treatment compliance between the two groups (98% for both arms), and the percentage of adverse events between the experimental group and the control group was comparable (58% vs. 72%, respectively), indicating a good drug safety profile [20]. Long-term extension data of this Phase 3 trial confirmed the efficacy of ferric maltol [21]. In fact, 97 of the 111 patients who completed the first 12 study weeks were enrolled in an open-label trial, receiving ferric maltol 30 mg twice a day, for an additional 52 weeks [21]. Patients who were treated with the placebo in the previous phase were switched to oral iron [21]. A mean increase of 3.07 g/dL in Hb concentration was found after 64 weeks of treatment [21]. Interestingly, an Hb mean increase of 2.19 g/dL was reported in the switch population [21]. Resolution of anemia occurred in over 80% of patients, and adherence to therapy was maintained in 84% of cases [21]. The drug appeared safe, as only 27 patients (24%) experienced drug-related adverse events (abdominal pain, constipation, flatulence, and diarrhea), and most of them were mild or moderate in intensity [21]. Similarly, a recent Cochrane review highlighted an acceptable safety profile for ferric maltol, as fewer adverse events and serious adverse events were reported in patients treated with ferric maltol, as compared to the placebo (51% vs. 71% and 8% vs. 13%; low certainty
J. Clin. Med. 2020, 9, 1536 6 of 10
evidence for both findings) [22]. Furthermore, preliminary data from an ongoing observational cohort study showed that two-thirds of the patients treated with ferric maltol achieved normalization of Hb levels after three months of oral supplementation in a real-life setting [23]. A real-life cohort study investigated IBD patient's tolerability toward ferric maltol [24]. It was well tolerated by 67% of patients, and 50% of patients, who did not t
https://res.mdpi.com/d_attachment/jcm/jcm-09-01536/article_deploy/jcm-09-01536.pdf
Great news. Acted fast. Great pedigree. Sounds very motivated.
New start for Shield. So much to come IMO.
Good post Shandy btw
FinnCap 22/05/2020
Shield Therapeutics (STX): Corp
FY 2019 results
Shield reported FY 2019 results that showed sustained momentum from Norgine’s promotional activity of Feraccru in England and Germany, with in-market pack volumes c.70% higher than in 2018. Revenues of £0.7m compared with £11.9m in 2018, which included £11m of milestones. This resulted in an adjusted net loss of £6.3m (vs +£1.1m). Net cash at 30 June was £4.1m, providing a cash runway into Q1 2021, which excludes potential significant up-front payments and milestones for US rights to Accrufer, which are currently being negotiated. Despite minor changes to forecasts, reflecting the later-than-modelled introduction of Feraccru/Accrufer into the broader EU market and US, we reiterate our 350p target price, which reflects the long-term nature of market exclusivity, peak market share (20% assumption) and rolling forward the start year for our DCF calculation, rather than near-term sales. This excludes the potential value of the US milestone, which we have stated in the past could be $50m with $100m+ of commercial milestones.
As expected really. Apart from Chairman stepping down. That’s business !
Seem more enthusiastic on using the H2H data.
US deal GOT TO happen soon !!!
China sounds promising
Junior formulation will be a hit
OT20 progress.
Slower than us holders would like I suppose , but the best things aren’t rushed !
GLA.
A few weak holders flushed out as always.
If the selling does stop , I’d expect the market re rates the SP well above 75p in anticipation of news and results.
A positive result would be so huge that the jump in price on opening would prevent people getting in anywhere under £2/3 maybe.
People buy on anticipation , this will now start building as we get closer to the all important results.
Or they get taken over.
IMO / DYOR etc